167 related articles for article (PubMed ID: 29100868)
1. Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation.
Wagener JS; Millar SJ; Mayer-Hamblett N; Sawicki GS; McKone EF; Goss CH; Konstan MW; Morgan WJ; Pasta DJ; Moss RB
J Cyst Fibros; 2018 Jul; 17(4):503-510. PubMed ID: 29100868
[TBL] [Abstract][Full Text] [Related]
2. Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation.
Sawicki GS; Konstan MW; McKone EF; Moss RB; Lubarsky B; Suthoff E; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan WJ; Duncan ME; Yang Y
Pulm Ther; 2022 Dec; 8(4):385-395. PubMed ID: 36319933
[TBL] [Abstract][Full Text] [Related]
3. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening.
Thauvin-Robinet C; Munck A; Huet F; Génin E; Bellis G; Gautier E; Audrézet MP; Férec C; Lalau G; Georges MD; Claustres M; Bienvenu T; Gérard B; Boisseau P; Cabet-Bey F; Feldmann D; Clavel C; Bieth E; Iron A; Simon-Bouy B; Costa C; Medina R; Leclerc J; Hubert D; Nové-Josserand R; Sermet-Gaudelus I; Rault G; Flori J; Leroy S; Wizla N; Bellon G; Haloun A; Perez-Martin S; d'Acremont G; Corvol H; Clément A; Houssin E; Binquet C; Bonithon-Kopp C; Alberti-Boulmé C; Morris MA; Faivre L; Goossens M; Roussey M; ; Girodon E
J Med Genet; 2009 Nov; 46(11):752-8. PubMed ID: 19880712
[TBL] [Abstract][Full Text] [Related]
4. Clinical phenotype of cystic fibrosis patients with the G551D mutation.
Comer DM; Ennis M; McDowell C; Beattie D; Rendall J; Hall V; Elborn JS
QJM; 2009 Nov; 102(11):793-8. PubMed ID: 19734299
[TBL] [Abstract][Full Text] [Related]
5. Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation.
Mondejar-Lopez P; Zolin A; Garcia-Marcos PW; Pastor-Vivero MD; Rosa-Silvestre M; de Asis Sanchez-Martinez F; Salvatore D; Cimino G; Majo F; Sole-Jover A; Asensio de la Cruz O; Calderazzo MA; Pizzamiglio G; Castillo-Corullon S; Alvarez-Fernandez A; Gartner S; Padoan R; Carnovale V; Salvatore M; Moya-Quiles MR; Orenti A; Glover G; Sanchez-Solis M
Respir Med; 2022 Feb; 192():106736. PubMed ID: 35032736
[TBL] [Abstract][Full Text] [Related]
6. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
[TBL] [Abstract][Full Text] [Related]
7. Rapid lung function decline in adults with early-stage cystic fibrosis lung disease.
Dasenbrook EC; Fink AK; Schechter MS; Sanders DB; Millar SJ; Pasta DJ; Mayer-Hamblett N
J Cyst Fibros; 2020 Jul; 19(4):527-533. PubMed ID: 31870629
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
[TBL] [Abstract][Full Text] [Related]
9. Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T - a case report.
Welsner M; Straßburg S; Taube C; Sutharsan S
BMC Pulm Med; 2019 Apr; 19(1):76. PubMed ID: 30975115
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
[TBL] [Abstract][Full Text] [Related]
12. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.
Sawicki GS; Van Brunt K; Booth J; Bailey E; Millar SJ; Konstan MW; Flume PA
J Cyst Fibros; 2022 Jan; 21(1):96-103. PubMed ID: 34289939
[TBL] [Abstract][Full Text] [Related]
13. Patients with cystic fibrosis having a residual function mutation: Data from the Italian registry.
Salvatore D; Padoan R; Buzzetti R; Amato A; Giordani B; Ferrari G; Majo F
Pediatr Pulmonol; 2019 Feb; 54(2):150-157. PubMed ID: 30561903
[TBL] [Abstract][Full Text] [Related]
14. Year to year change in FEV
De Boeck K; Zolin A
J Cyst Fibros; 2017 Mar; 16(2):239-245. PubMed ID: 27745801
[TBL] [Abstract][Full Text] [Related]
15. Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline.
Sawicki GS; McKone EF; Millar SJ; Pasta DJ; Konstan MW; Lubarsky B; Wagener JS
Am J Respir Crit Care Med; 2017 Jun; 195(12):1673-1676. PubMed ID: 28617084
[No Abstract] [Full Text] [Related]
16. Registry-based study in people with cystic fibrosis and an
Higgins M; Farietta T; Campbell D; Liu M; Ostrenga J; Elbert A; Shih J; Volkova N
BMJ Open Respir Res; 2023 May; 10(1):. PubMed ID: 37230763
[TBL] [Abstract][Full Text] [Related]
17. Variation in lung function and nutritional decline in cystic fibrosis by genotype: An analysis of the Canadian cystic fibrosis registry.
Leung GJ; Cho TJ; Kovesi T; Hamid JS; Radhakrishnan D
J Cyst Fibros; 2020 Mar; 19(2):255-261. PubMed ID: 31253541
[TBL] [Abstract][Full Text] [Related]
18. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
[TBL] [Abstract][Full Text] [Related]
19. Modeling cystic fibrosis disease progression in patients with the rare CFTR mutation P67L.
MacKenzie IER; Paquette V; Gosse F; George S; Chappe F; Chappe V
J Cyst Fibros; 2017 May; 16(3):335-341. PubMed ID: 28392015
[TBL] [Abstract][Full Text] [Related]
20. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
